Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro.
1992588 citationsT. Kuber Sampath, Peter V. Hauschka et al.Journal of Biological Chemistryprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Halina Sasak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Halina Sasak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Halina Sasak more than expected).
This network shows the impact of papers produced by Halina Sasak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Halina Sasak. The network helps show where Halina Sasak may publish in the future.
Co-authorship network of co-authors of Halina Sasak
This figure shows the co-authorship network connecting the top 25 collaborators of Halina Sasak.
A scholar is included among the top collaborators of Halina Sasak based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Halina Sasak. Halina Sasak is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
8 of 8 papers shown
1.
LePage, Doreen, Halina Sasak, María José Guillén, et al.. (2007). Antitumor activity of Zalypsis® (PM00104) in experimental models of bladder, gastric and liver cancer.. Molecular Cancer Therapeutics. 6.5 indexed citations
2.
Muñoz, María José, Enrique Álvarez, Teresa Martı́nez, et al.. (2007). JNK activation as an in vivo marker of Aplidin® activity.. Cancer Research. 67. 5580–5580.4 indexed citations
3.
Sasak, Halina, Doreen LePage, Carmen Cuevas, et al.. (2007). Antitumor activity of Aplidin® in combination with Velcade® (bortezomib) in human multiple myeloma.. 67. 4762–4762.1 indexed citations
4.
LePage, Doreen, Douglas Lazarus, Mariano J. Elices, et al.. (2006). Aplidin® combination with chemotherapeutic agents in human melanoma tumors. 66. 504–504.1 indexed citations
5.
Elices, Mariano J., Halina Sasak, Wendy Grant, et al.. (2005). Antitumor activity of the novel investigational compound PM00104. 65. 1384–1384.2 indexed citations
Sampath, T. Kuber, Peter V. Hauschka, William K. Jones, et al.. (1992). Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro.. Journal of Biological Chemistry. 267(28). 20352–20362.588 indexed citations breakdown →
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.